Cargando…
New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24− non-hematopoietic rare cell phenotype with breast cancer residual disease
BACKGROUND: Breast cancer residual disease assessment in early-stage patients has been challenging and lacks routine identification of adjuvant therapy benefit and objective measure of therapy success. Liquid biopsy assays targeting tumor-derived entities are investigated for minimal residual diseas...
Autores principales: | Schreier, Stefan, Budchart, Prapaphan, Borwornpinyo, Suparerk, Arpornwirat, Wichit, Lertsithichai, Panuwat, Chirappapha, Prakasit, Triampo, Wannapong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470072/ https://www.ncbi.nlm.nih.gov/pubmed/36100762 http://dx.doi.org/10.1007/s00432-022-04330-5 |
Ejemplares similares
-
Circulating erythroblast abnormality associated with systemic pathologies may indicate bone marrow damage
por: Schreier, Stefan, et al.
Publicado: (2021) -
Idiopathic granulomatous mastitis: A retrospective cohort study between 44 patients with different treatment modalities
por: Chirappapha, Prakasit, et al.
Publicado: (2018) -
Sentinel lymph node biopsy after neoadjuvant treatment of breast cancer using blue dye, radioisotope, and indocyanine green: Prospective cohort study
por: Chirappapha, Prakasit, et al.
Publicado: (2020) -
The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?
por: Schreier, Stefan, et al.
Publicado: (2020) -
Large Mammary Paget Disease without Underlying Breast Carcinoma
por: Chirappapha, Prakasit, et al.
Publicado: (2022)